Skip to main content
. 2021 Nov 10;27(24):6687–6695. doi: 10.1158/1078-0432.CCR-21-2283

Figure 2.

Figure 2. Estimates of TFS, with and without toxicity, and other survival states over the 42-month period since randomization, according to treatment group, among 847 IMDC intermediate- and poor-risk patients. Toxicity is defined alternatively by grade ≥3 TRAEs (A) and grade ≥2 TRAEs (B). NIVO+IPI, nivolumab plus ipilimumab; Rx, therapy; SUN, sunitinib.

Estimates of TFS, with and without toxicity, and other survival states over the 42-month period since randomization, according to treatment group, among 847 IMDC intermediate- and poor-risk patients. Toxicity is defined alternatively by grade ≥3 TRAEs (A) and grade ≥2 TRAEs (B). NIVO+IPI, nivolumab plus ipilimumab; Rx, therapy; SUN, sunitinib.